Development of novel immunotherapy using combination of inactivated viral particle and autologous tumor vaccine for malignant glioma
| Project/Area Number |
24791485
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | University of Tsukuba |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 不活化ウイルス粒子 / 自家腫瘍ワクチン / 脳腫瘍 / 新規免疫療法 |
|---|
| Outline of Final Research Achievements |
Hemagglutinating virus of Japan envelope (HVJ-E) derived from inactivated replication-defective Sendai virus was originally developed as a versatile drug delivery system. We had shown the ability of HVJ-E itself to enhance anti-tumor immunity through activation of effector T cells and natural killer cells and inhibition of regulatory T cells in glioma mouse models. In the present study, we have shown that the addition of systemic activation of tumor specific immunity by autologous tumor vaccination to local inhibition of immune tolerance by HVJ-E leads to synergistic activation of anti-tumor immunity against intracranial glioma.
|
Report
(4 results)
Research Products
(5 results)
